April 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Retinoic acid helps activate hair growth in people with common hair loss by working on a specific cell growth pathway.
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
January 2026 in “Frontiers in Medicine” FFA and FAPD might be related or stages of the same disease.
December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
January 2026 in “International Journal of Dermatology” Treatment improved scalp conditions and hair loss with no recurrence after 1 year.
2 citations
,
July 2020 in “Behavioural Brain Research” Changing neuroactive steroids in baby male rats affects their memory and learning differently as they grow up.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” A new treatment plan helps manage folliculitis decalvans effectively.
November 2025 in “Caderno Pedagógico” Cedar and castor oils with high frequency can help hair growth in androgenetic alopecia.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
2 citations
,
September 1992 in “Steroids” New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
88 citations
,
April 1981 in “Molecular and cellular biochemistry” 305 citations
,
March 2008 in “AJP Endocrinology and Metabolism” SSAT is a key enzyme affecting cell growth and metabolism, with potential but risky use in disease treatment.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
29 citations
,
May 1988 in “Clinical Endocrinology” Fibroblasts help understand androgen resistance at the cellular level.
17 citations
,
January 2015 in “International Journal of Trichology” Frontal fibrosing alopecia may affect nails and could be a type of lichen planus, treatable with certain medications.
4 citations
,
April 2018 in “Journal of Investigative Dermatology” Hydroxypinacolone retinoate is a potent anti-aging ingredient for skin that is more effective and less irritating than other forms of retinoids.
54 citations
,
December 2004 in “PubMed” Cyclosporin A vesicles effectively regrow hair and reduce inflammation in alopecia areata.
1 citations
,
May 2022 in “Revista Contemporânea” Combining two treatments for hair loss works better than using just one.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
December 2024 in “PubMed” TrichoFoam™ effectively delivers multiple hair loss treatments, maintaining their stability and effectiveness.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
117 citations
,
February 1996 in “International Journal of Dermatology” A 300 mg monthly pulse of prednisolone effectively and safely treats widespread alopecia areata.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.